Rotigotine transdermal patch in combination therapy for Parkinson's disease observations in routine clinical practice

Current Medical Research and Opinion

Volumn 27, Issue 10, 2011, Pages 1899-1905

  Ceballos Baumann, Andres ^a   Hck, Hermann Josef ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UCB PHARMA   (Belgium)

Author keywords

Combination therapy; Dopamine agonist; Levodopa dose reduction; Parkinson's disease; Rotigotine transdermal patch; Routine clinical practice; Sleep quality

Indexed keywords

LEVODOPA; ROTIGOTINE;

ADULT; AGED; APPLICATION SITE REACTION; ARTICLE; BLOOD PRESSURE FLUCTUATION; BODY MASS; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPHAGIA; FATIGUE; FEMALE; FOLLOW UP; HALLUCINATION; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MARASMUS; MULTICENTER STUDY; MUSCULOSKELETAL STIFFNESS; NAUSEA; OPEN STUDY; PANCREATITIS; PARKINSON DISEASE; PROSPECTIVE STUDY; SIDE EFFECT; SLEEP QUALITY; TREMOR; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, CUTANEOUS; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PROSPECTIVE STUDIES; SLEEP; TETRAHYDRONAPHTHALENES; THIOPHENES; TIME FACTORS;

EID: 80052985435     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.611630     Document Type: Article

References (29)

1. Schapira AHV, Emre M, Jenner P, et al. Levodopa in the treatment of Parkinson's disease. Eur J Neurol 2009;16:982-9
2. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-58 (Pubitemid 36041148)
3. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000;342:1484-91 (Pubitemid 30318272)
4. Fahn S, Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 2005;252(Suppl 4):37-42
5. Stocchi F. Dopamine receptor agonists in the treatment of advanced Parkinson's disease. Parkinsonism Relat Disord 2009;15S:S54-7
6. Talati R, Baker WL, Patel AA, et al. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis. Int J Clin Pract 2009;63:613-23
7. Bonuccelli U, Del Dotto P, Rascol O. Role of dopamine receptor agonists in the treatment of early Parkinson's disease. Parkinsonism Relat Disord 2009; 15S:S44-53
8. Watts RL, Jankovic J, Waters C, et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007; 68:272-6 (Pubitemid 46148338)
9. Giladi N, Boroojerdi B, Korczyn AD, et al. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007;22:2398-404 (Pubitemid 351155987)
10. LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system. PREFER Study. Neurology 2007;68:1262-7 (Pubitemid 46625971)
11. Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007;6:513-20 (Pubitemid 46734759)
12. LeWitt PA, Boroojerdi B, MacMahon D, et al. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. Clin Neuropharmacol 2007;30:256-65 (Pubitemid 47511505)
13. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8:464-74
14. Neupro transdermal patch. Package Label. Available at: http://www.fachinfo. de/data/fi/jsearch?praep (Last accessed 18 May 2011)
15. Chaudhuri KR, Pal S, DiMarco A, et al. The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002;73:629-35 (Pubitemid 35448845)
16. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, et al. eds. Recent Developments in Parkinson's Disease, Vol. 2. Florham Park: MacMillan Healthcare Information, 1987:153-63
17. Guidelines of the German Neurological Society (Leitlinien für Diagnostik und Therapie in der Neurologie; in German). Available at: http://www. uni-duesseldorf.de/AWMF/ll/030-010.htm (Last accessed 18 May 2011)
18. Leopold NA, Polansky M, Hurka MR. Drug adherence in Parkinson's disease. Mov Disord 2004;19:513-17
19. Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson's disease. Mov Disord 2005;20:1502-7 (Pubitemid 43072661)
20. Grosset D, Antonini A, Canesi M, et al. Adherence to antiparkinson medication in a multicenter European study. Mov Disord 2009;24:826-32
21. Setter SM. Assessing the impact of ease of administration and tolerability on treatment choices in Parkinson's disease. Neurol Clin 2008;26:S45-63
22. Grosset D, Grosset K, Emmermann A, et al. Improved self-reported compliance with transdermal (patch) versus oral medication in Parkinson's disease patients. Eur J Neurol 2006;13(Suppl 2):88-9 (abstract P1175)
23. Schnitzler A, Leffers K-W, Häck H-J. High compliance with rotigotine transdermal patch in the treatment of idiopathic Parkinson's disease. Parkinsonism Relat Disord 2010;16:513-16
24. Miller N, Allcock L, Hildreth AJ, et al. Swallowing problems in Parkinson disease: frequency and clinical correlates. J Neurol Neurosurg Psychiatry 2009;80:1047-9
25. Plowman-Prine EK, Sapienza CM, Okun MS, et al. The relationship between quality of life and swallowing in Parkinson's disease. Mov Disord 2009;24:1352-8
26. Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of Parkinson's disease. Clin Neuropharmacol 1988;11:512-19 (Pubitemid 19006460)
27. Giladi N, Fichtner A, Poewe W, et al. Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson's disease. J Neural Transm 2010;117:1395-9
28. Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011;26:90-9
29. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010;67:589-95